Akeso (9926.HK) said China’s NMPA has cleared its next-generation B7-H3 targeting antibody-drug conjugate (ADC) AK157D1 to enter clinical trials. The clearance is a positive regulatory milestone that can support future trial progress and market confidence, though no efficacy or financial impact was disclosed.
Akeso (9926.HK) said China’s NMPA has cleared its next-generation B7-H3 targeting antibody-drug conjugate (ADC) AK157D1 to enter clinical trials. The clearance is a positive regulatory milestone that can support future trial progress and market confidence, though no efficacy or financial impact was disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
